Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudeep PharmaBOM:544619 -1.10%18 EV-to-FCF is -493.03 as of Aug. 04, 2026. GuruFocus rates BOM:544619 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 572 Drug Manufacturers companies, Sudeep Pharma ranks worse than 174825% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sudeep Pharma's Enterprise Value is ₹98,607 Mil.
Sudeep Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-200 Mil. Therefore, Sudeep Pharma's EV-to-FCF for today is -493.03.
The historical rank and industry rank for Sudeep Pharma's EV-to-FCF or its related term are showing as below:
BOM:544619'
s EV-to-FCF Range Over the Past 10 Years
Min: -485.72 Med: -368.67 Max: -302.08
Current: -469.37
During the past 4 years, the highest EV-to-FCF of Sudeep Pharma was -302.08. The lowest was -485.72. And the median was -368.67.
BOM:544619's EV-to-FCF is ranked worse than 100% of 572
companies
in the Drug Manufacturers industry
Industry Median: 21.06
vs BOM:544619: -469.37
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sudeep Pharma's PE Ratio (TTM) for today is calculated as:
Sudeep Pharma's share price for today is ₹868.55.
Sudeep Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹11.198.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sudeep Pharma EV-to-FCF Related Terms
Sudeep Pharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Sudeep Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sudeep Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudeep Pharma EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sudeep Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sudeep Pharma's EV-to-FCF falls into.
Sudeep Pharma's current Enterprise Value is ₹98,607 Mil.
Sudeep Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-200 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sudeep Pharma (BOM:544619) has a EV-to-FCF of -493.03 as of Aug. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sudeep Pharma and its competitors. According to the industry distribution chart, Sudeep Pharma ranks #999999 out of 572 companies in the Drug Manufacturers industry.
Is Sudeep Pharma's EV-to-FCF too high?
Sudeep Pharma's current EV-to-FCF is -493.03. Based on the distribution chart, Sudeep Pharma ranks #999999 out of 572 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sudeep Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sudeep Pharma's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sudeep Pharma ranks #999999 out of 572 companies for EV-to-FCF. This places Sudeep Pharma in the lower half of its industry. The industry median EV-to-FCF is 21.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.06, based on 572 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sudeep Pharma and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sudeep Pharma's current EV-to-FCF is -493.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudeep Pharma stock overvalued right now?
Sudeep Pharma (BOM:544619) has a current EV-to-FCF of -493.03. The current EV-to-FCF is -493.03. Sudeep Pharma's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sudeep Pharma (BOM:544619), the current EV-to-FCF is -493.03 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
18GF Score
Get the complete analysis for BOM:544619
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544619 has been successfully added to your 
